Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 28:11:743231.
doi: 10.3389/fonc.2021.743231. eCollection 2021.

Novel Insights From the Germline Landscape of Breast Cancer in Brazil

Daniel Barbalho  1 , Renata Sandoval  2 , Erika Santos  2 , Janina Pisani  2 , Carla Quirino  2 , Bernardo Garicochea  2   3 , Benedito Rossi  2 , Maria Isabel Achatz  2
Affiliations

Novel Insights From the Germline Landscape of Breast Cancer in Brazil

Daniel Barbalho et al. Front Oncol. .

Abstract

Introduction: Breast cancer patients with germline pathogenic variants may benefit from risk-reducing surgeries, intensive screening, and targeted cancer therapies. There is a paucity of data regarding prevalence and distribution of germline pathogenic variants in the Brazilian population. Our primary endpoint was the description of prevalence and distribution of germline pathogenic variants among breast cancer patients who underwent next-generation sequencing (NGS) panel testing. Secondary endpoint was the assessment of predictive factors of a positive test.

Methods: We analyzed NGS results, personal, and family history data from a prospectively collected cohort of breast cancer patients from August 2013 to May 2019. Exact logistic regression was used to perform multivariable analysis.

Results: Of 370 breast cancer patients, we found 59 pathogenic variants in 57 (15%) patients. Pathogenic variants were identified in BRCA1 (24%), ATM (14%), BRCA2 (10%), TP53 (8%), PALB2 (8%), CHEK2 (7%), CDH1 (3%), RAD51C (3%), MITF (2%), PMS2 (2%), RAD51D (2%), and TERT (2%). Monoallelic MUTYH pathogenic variants were found in 15%. After multivariable analysis, age of diagnosis (OR 0.89, 95% CI: 0.81-0.95, for each year increase), triple-negative subtype (OR 17.2, 95% CI: 3.74-114.72), and number of breast cancers in the family (OR 2.46, 95% CI 1.57-4.03, for each additional case) were associated with BRCA1 pathogenic variants. In the present study, a quarter of triple-negative breast cancer patients harbored a germline pathogenic variant and two-thirds of those were BRCA1 carriers.

Conclusions: Prevalence and distribution of germline pathogenic variants in this Brazilian sample of breast cancer patients are mostly similar to other populations. However, there is a trend to an overrepresentation of TP53 pathogenic variants that merits confirmation in further studies. Early-onset breast cancer patients should be offered genetic counseling, particularly those with triple-negative subtype.

Keywords: Brazil; breast neoplasms; genetic predictive testing; genetic predisposition to breast cancer; high-throughput nucleotide sequencing.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Distribution of germline pathogenic variants.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. De Oliveira Santos M. Estimativa/2020 – Incidência De Câncer No Brasil. Rev Bras Cancerol (2020) 66(1):1. doi: 10.32635/2176-9745.rbc.2020v66n1.927 - DOI
    1. Buys S, Sandbach JF, Gammon A, Patel G, Kidd J, Brown K, et al. . A Study of Over 35,000 Women With Breast Cancer Tested With a 25-Gene Panel of Hereditary Cancer Genes. Cancer (2017) 123(10):1721–30. doi: 10.1002/cncr.30498 - DOI - PubMed
    1. King MC. “The Race” to Clone BRCA1. Sci (80-) (2014) 343(6178):1462–5. doi: 10.1126/science.1251900 - DOI - PubMed
    1. Shendure J, Balasubramanian S, Church GM, Gilbert W, Rogers J, Schloss JA, et al. . DNA Sequencing at 40: Past, Present and Future. Nature (2017) 550(7676):345–53. doi: 10.1038/nature24286 - DOI - PubMed
    1. Couch FJ, Shimelis H, Hu C, Hart SN, Polley EC, Na J, et al. . Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer. JAMA Oncol (2017) 3(9):1190–6. doi: 10.1001/jamaoncol.2017.0424 - DOI - PMC - PubMed